Your browser doesn't support javascript.
loading
Outcomes in Patients With Transcatheter Aortic Valve Replacement and Left Main Stenting: The TAVR-LM Registry.
Chakravarty, Tarun; Sharma, Rahul; Abramowitz, Yigal; Kapadia, Samir; Latib, Azeem; Jilaihawi, Hasan; Poddar, Kanhaiya Lal; Giustino, Gennaro; Ribeiro, Henrique B; Tchetche, Didier; Monteil, Benoit; Testa, Luca; Tarantini, Giuseppe; Facchin, Michela; Lefèvre, Thierry; Lindman, Brian R; Hariri, Babak; Patel, Jigar; Takahashi, Nobuyuki; Matar, George; Mirocha, James; Cheng, Wen; Tuzcu, Murat E; Sievert, Horst; Rodés-Cabau, Josep; Colombo, Antonio; Finkelstein, Ariel; Fajadet, Jean; Makkar, Raj R.
Afiliação
  • Chakravarty T; Cedars-Sinai Heart Institute, Los Angeles, California.
  • Sharma R; Cedars-Sinai Heart Institute, Los Angeles, California.
  • Abramowitz Y; Cedars-Sinai Heart Institute, Los Angeles, California; Tel Aviv Medical Center, Tel Aviv, Israel.
  • Kapadia S; Cleveland Clinic, Cleveland, Ohio.
  • Latib A; San Raffaele Scientific Institute and EMO-GVM Centro Cuore Columbus, Milan, Italy.
  • Jilaihawi H; Cedars-Sinai Heart Institute, Los Angeles, California.
  • Poddar KL; Cleveland Clinic, Cleveland, Ohio.
  • Giustino G; San Raffaele Scientific Institute and EMO-GVM Centro Cuore Columbus, Milan, Italy.
  • Ribeiro HB; Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.
  • Tchetche D; Clinique Pasteur, Toulouse, France.
  • Monteil B; Clinique Pasteur, Toulouse, France.
  • Testa L; IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
  • Tarantini G; Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
  • Facchin M; Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
  • Lefèvre T; Hopital Privé Jacques Cartier, Massy, France.
  • Lindman BR; Washington University School of Medicine, St. Louis, Missouri.
  • Hariri B; Cedars-Sinai Heart Institute, Los Angeles, California.
  • Patel J; Cedars-Sinai Heart Institute, Los Angeles, California.
  • Takahashi N; Cedars-Sinai Heart Institute, Los Angeles, California.
  • Matar G; Cedars-Sinai Heart Institute, Los Angeles, California.
  • Mirocha J; Cedars-Sinai Heart Institute, Los Angeles, California.
  • Cheng W; Cedars-Sinai Heart Institute, Los Angeles, California.
  • Tuzcu ME; Cleveland Clinic, Cleveland, Ohio.
  • Sievert H; CardioVascular Center Frankfurt CVC, Frankfurt, Germany.
  • Rodés-Cabau J; Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.
  • Colombo A; San Raffaele Scientific Institute and EMO-GVM Centro Cuore Columbus, Milan, Italy.
  • Finkelstein A; Tel Aviv Medical Center, Tel Aviv, Israel.
  • Fajadet J; Clinique Pasteur, Toulouse, France.
  • Makkar RR; Cedars-Sinai Heart Institute, Los Angeles, California. Electronic address: makkarr@cshs.org.
J Am Coll Cardiol ; 67(8): 951-960, 2016 Mar 01.
Article em En | MEDLINE | ID: mdl-26916485
BACKGROUND: A percutaneous approach with transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI) of the left main coronary artery (LM) is frequently used in high-risk patients with coexisting aortic stenosis and LM disease. Outcomes of TAVR plus LM PCI have not been previously reported. OBJECTIVES: The primary objective of the TAVR-LM registry is to evaluate clinical outcomes in patients undergoing TAVR plus LM PCI. METHODS: Clinical, echocardiographic, computed tomographic, and angiographic characteristics were retrospectively collected in 204 patients undergoing TAVR plus LM PCI. In total, 128 matched patient pairs were generated by performing 1:1 case-control matching between 167 patients with pre-existing LM stents undergoing TAVR and 1,188 control patients undergoing TAVR without LM revascularization. RESULTS: One-year mortality (9.4% vs. 10.2%, p = 0.83) was similar between the TAVR plus LM PCI cohort and matched controls. One-year mortality after TAVR plus LM PCI was not different in patients with unprotected compared with protected LMs (7.8% vs. 8.1%, p = 0.88), those undergoing LM PCI within 3 months compared with those with LM PCI greater than 3 months before TAVR (7.4% vs. 8.6%, p = 0.61), and those with ostial versus nonostial LM stents (10.3% vs. 15.6%, p = 0.20). Unplanned LM PCI performed because of TAVR-related coronary complication, compared with planned LM PCI performed for pre-existing LM disease, resulted in increased 30-day (15.8% vs. 3.4%, p = 0.013) and 1-year (21.1% vs. 8.0%, p = 0.071) mortality. CONCLUSIONS: Despite the anatomic proximity of the aortic annulus to the LM, TAVR plus LM PCI is safe and technically feasible, with short- and intermediate-term clinical outcomes comparable with those in patients undergoing TAVR alone. These results suggest that TAVR plus LM PCI is a reasonable option for patients who are at high risk for surgery.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article